Overview
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
Description
To determine the optimal schedule for three-dimensional verification imaging and necessary re-planning of patients undergoing IMPT for a rapidly changing tumor (small cell lung cancer).
- To determine the rate of cardiac toxicities from IMPT in patients with small cell lung cancer compared with historical controls receiving photon-based treatment.
- To determine the rate of pneumonitis and esophagitis from IMPT and compare with historical controls receiving photon based treatment.
Eligibility
Inclusion Criteria:
- Pathologically confirmed small cell lung cancer, limited or extensive stage.
- Patients who are offered thoracic radiotherapy with intensity-modulated proton therapy (IMPT) techniques delivering 30-66 Gy in 15-33 fractions at 2 Gy per fraction, at the recommendation of the treating radiation oncologist.
- Age 18 or greater
Exclusion Criteria:
- Prior radiation therapy which would provide significant dose overlap with the planned target volume(s)
- Pregnancy